Drug Type Antibody drug conjugate (ADC) |
Synonyms SGN CD19B |
Target |
Action modulators, inhibitors |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), DNA inhibitors(DNA inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC42H39N5O7 |
InChIKeyOMRPLUKQNWNZAV-CONSDPRKSA-N |
CAS Registry1222490-34-7 |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 1 | United States | 01 Feb 2016 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | United States | 01 Feb 2016 | |
| Follicular Lymphoma | Phase 1 | United States | 01 Feb 2016 |






